Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03140813 · ClinicalTrials.gov registry record · Phase 1
An Initial Study of AZD7325 in Adults With Fragile X Syndrome
A Phase 1 study of Fragile X Syndrome, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03140813 is a Phase 1 study of Fragile X Syndrome that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 15 participants, below the 101-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03140813, a Phase 1 study of Fragile X Syndrome, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the safety, tolerability and blood pharmacodynamics of treatment with oral administration of AZD7325 at 5 mg BID, 15 mg BID, and placebo BID, in adults with Fragile X Syndrome. The study also will also investigate measures of efficacy and biomarkers during treatment.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG AZD7325 (High-Dose)
- DRUG AZD7325 (Low-Dose)
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2020-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03140813
The ClinicalTrials.gov registry entry for NCT03140813 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 16 other Fragile X Syndrome trials with a reported enrollment target (85% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fragile X Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03140813 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03140813 about?
NCT03140813 is a clinical study titled "An Initial Study of AZD7325 in Adults With Fragile X Syndrome". This study will investigate the safety, tolerability and blood pharmacodynamics of treatment with oral administration of AZD7325 at 5 mg BID, 15 mg BID, and placebo BID, in adults with Fragile X Syndrome. The study also will also investigate measures of efficacy and biomarkers during treatment.
What is the current status of trial NCT03140813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-01-16. Estimated completion is 2020-06-18.
What conditions does trial NCT03140813 study?
This clinical trial studies the following conditions: Fragile X Syndrome.
What interventions are being tested in trial NCT03140813?
The interventions under investigation include: Placebo oral capsule (DRUG), AZD7325 (High-Dose) (DRUG), AZD7325 (Low-Dose) (DRUG).
Who is sponsoring clinical trial NCT03140813?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03140813 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fragile X Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)
COMPLETED · Phase 1
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant
RECRUITING · NA
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age
RECRUITING · NA
-
Speech-in-noise Perception in Autism and Fragile X
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.